Breaking News

Lantern Pharma Chooses Reprocell to Support Phase 2 Harmonic Trial

Reprocell will produce specimen collection kits, process patient samples and store biomaterial from patients.

Reprocell USA, a contract research organization (CRO), has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)”. The Harmonic study is being conducted to determine clinical advantages for Lantern Pharma’s investigational new drug LP-300 in combination with carboplatin and pemetrexed in patients who are never smoker...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters